Results - Announcements
Dr Reddys Laboratories Ltd share price softened by 1.17% to Rs 1224.5. The Company's net profit jumped 109.64% to Rs 913.2 crore, while revenue from operations slightly gained 7.44% to Rs 8670.8 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.82 lakh crore, gaining 3.59%. It has eased by 2.75% over last one week and edged lower by 2.21% in last one month while the market capitalization of Dr Reddys Laboratories Ltd has slipped by 0.60% and 6.24% in the same period respectively.
Profit before tax (PBT) of Dr Reddys Laboratories Ltd stood at Rs 1227.6 crore in Q3 FY26, tanking 29.64% year-on-year, and jumping 121.87% quarter-on-quarter. EBITDA came in at Rs 1574 crore, declining 6.62% YoY and surging by 211.64% sequentially.
Total expenses slightly declined by 3.63% to Rs 7493.9 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1661.0 crore, inching up 0.44% YoY, while employee benefits expense was at Rs 1611.9 crore, slipping by 2.40% YoY.
For the TTM ended FY26, revenue from operations posted a slight growth of 3.19% to Rs 33593.3 crore, while net profit plunged by 27.38% to Rs 4157.6 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 780390% to Rs 5095.1 crore, and PBT tumbled by 29.78% to Rs 5392.7 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 5673.7 crore in FY26, as against Rs 4642.8 crore in FY25.
Dr Reddys Laboratories Ltd slipped 4.32% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 13.52% during the same period.